Processa Pharmaceuticals, Inc.
next-generation chemotherapy and small molecule pharmaceuticals
PCSA · Nasdaq · United States
Share price · PCSA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PCSA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Oct 2026+25.0%
Nothing announced by PCSA that day or the session before.
- 29 Jul 2026-33.4%
- 28 Jul 2026+17.8%
Nothing announced by PCSA that day or the session before.
- 22 Jul 2026+13.4%
Nothing announced by PCSA that day or the session before.
- 11 Jun 2026+19.7%
Nothing announced by PCSA that day or the session before.
- 9 Jun 2026-15.9%
Nothing announced by PCSA that day or the session before.
- 2 Jun 2026+15.4%
Nothing announced by PCSA that day or the session before.
- 14 May 2026+20.4%
Nothing announced by PCSA that day or the session before.
- 19 Mar 2026-26.3%
Nothing announced by PCSA that day or the session before.
- 18 Dec 2025-41.6%
Share of unusual movement by asset
For each asset, the share of PCSA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
PCS499events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 50% |
| Sessions with no dated event | — | 50% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
PCS499No recent activity | Phase 2 | —Small molecule | Necrobiosis Lipoidica |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.8M | $180M | $183M-$5.2M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.7M | $0.2M | $3.3M-$2.0M operating cash flow | report ↗ |
| 2026-Q1 | — | $1.8M | $1.7M | $3.4M-$3.6M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.7M | $6.3M | $3.4M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.5M | $6.9M | $3.9M-$2.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.6M | $2.9M | $2.8M-$2.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.3M | $2.9M | $3.4M-$3.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.7M | $5.6M | $3.0M-$3.4M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.5M | $8.9M | $2.7M-$2.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.1M | $6.9M | $2.1M-$1.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.7M | $8.7M | $2.6M-$2.1M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $1.6M | $11M | $4.0M-$2.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $3.1M | $9.1M | $6.0M-$3.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.1M | $12M | $5.2M-$2.3M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $2.0M | $14M | $3.2M-$1.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.7M | $19M | $3.0M-$1.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $7.8M | $5.5M | $3.4M-$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 45 purchases ($225K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-08 | Ng George K · director, Chief Executive Officer | Option exercise | 1,600 | — | — | Form 4 |
| 2026-08-08 | Ng George K · director, Chief Executive Officer | Option exercise (derivative) | 1,600 | — | — | Form 4 |
| 2026-07-28 | GUJRATHI SHEILA · director | Award / grant (derivative) | 70,811.877 | — | — | Form 4 |
| 2026-07-28 | GUJRATHI SHEILA · director | Award / grant (derivative) | 12,311.279 | — | — | Form 4 |
| 2026-07-26 | Baluch Khoso · director | Award / grant (derivative) | 33,500 | — | — | Form 4 |
| 2026-07-26 | Guy Wendy · Chief Administrative Officer | Award / grant (derivative) | 9,450 | — | — | Form 4 |
| 2026-07-26 | Lin Patrick · Chief Business - Strategy Off | Award / grant (derivative) | 8,450 | — | — | Form 4 |
| 2026-07-26 | Neal James R · director | Award / grant (derivative) | 62,221 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 10 reporting institutions held 0.2M shares ($448K, 6.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Connective Capital Management, LLC | 70,736 | $179K |
| 2 | Stonepine Capital Management, LLC | 55,000 | $139K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 24,908 | $63K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 12,729 | $32K |
| 5 | VANGUARD FIDUCIARY TRUST CO | 10,857 | $27K |
| 6 | UBS Group AG | 2,531 | $6K |
| 7 | Tower Research Capital LLC (TRC) | 918 | $2K |
| 8 | CITIGROUP INC | 14 | $35 |
| 9 | JONES FINANCIAL COMPANIES LLLP | 7 | $17 |
| 10 | WELLS FARGO & COMPANY/MN | 6 | $15 |